Advertisement
AMRN vs IBRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and IBRX is a Buy.
AMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AMRN turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 43 of 55 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Indicator exited the oversold zone, 27 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on AMRN as a result. In 65 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.569) is normal, around the industry mean (-2.689). P/E Ratio (-9.958) is within average values for comparable stocks, (21.011). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
IBRX's Stochastic Oscillator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 119 of 123 cases where IBRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 84 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IBRX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.739) is normal, around the industry mean (2.974). P/E Ratio (-9.084) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | IBRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 74 | 36 | |
P/E GROWTH RATING 1..100 | 26 | 61 | |
SEASONALITY SCORE 1..100 | 6 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBRX's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for AMRN (67) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew somewhat faster than AMRN’s over the last 12 months.
IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to AMRN’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as IBRX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to IBRX’s over the last 12 months.
IBRX's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for AMRN (74) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew somewhat faster than AMRN’s over the last 12 months.
AMRN's P/E Growth Rating (26) in the Pharmaceuticals Other industry is somewhat better than the same rating for IBRX (61) in the Biotechnology industry. This means that AMRN’s stock grew somewhat faster than IBRX’s over the last 12 months.
| AMRN | IBRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Advances ODDS (%) | 3 days ago 73% | 14 days ago 87% |
| Declines ODDS (%) | 13 days ago 85% | 3 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while IBRX’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- IBRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 5 TA indicator(s) are bullish while IBRX’s TA Score has 4 bullish TA indicator(s).
- AMRN’s TA Score: 5 bullish, 3 bearish.
- IBRX’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а +4.09% price change this week, while IBRX (@Biotechnology) price change was -1.60% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.57%. For the same industry, the average monthly price growth was -5.94%, and the average quarterly price growth was +2.44%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.63%. For the same industry, the average monthly price growth was -10.78%, and the average quarterly price growth was -12.83%.
Reported Earning Dates
AMRN is expected to report earnings on Oct 28, 2026.
IBRX is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.57% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+2.63% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| STCE | 51.17 | 2.24 | +4.58% |
| Schwab Crypto Thematic ETF | |||
| THQ | 18.46 | 0.17 | +0.93% |
| abrdn Healthcare Opportunities Fund | |||
| XLUI | 22.85 | 0.09 | +0.40% |
| State Street Utilities Select Sector SPDR Premium Income ETF (XLUI) | |||
| MINT | 100.65 | 0.03 | +0.03% |
| PIMCO Enhanced Short Maturity Active Exchange-Traded Fund (MINT) | |||
| FOWF | 35.11 | N/A | N/A |
| Pacer Solactive Whitney Future of Warfare ETF (FOWF) | |||